www.impactjournals.com/oncotarget/
Oncotarget, 2017, Vol. 8, (No. 37), pp: 61935-61943 Research Paper
Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis Keng-Liang Wu1,2,3, Eng-Yen Huang4,5, Wen-Ling Yeh1, Chang-Chun Hsiao2,6 and Chung-Mou Kuo1,3 1
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
2
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Kaohsiung, Taiwan
3
Chang Gung University, College of Medicine, Kaohsiung, Taiwan
4
Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
5
School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Kaohsiung, Taiwan
6
Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Correspondence to: Chang-Chun Hsiao, email: [email protected] Keywords: colorectal cancer, galectin-3, carcinoembryonic antigen, cancer cell migration Received: February 09, 2017 Accepted: May 22, 2017 Published: June 27, 2017 Copyright: Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT In this study, we investigated the role of galectin-3 and carcinoembryonic antigen (CEA) in metastasis and survival of colorectal cancer (CRC) patients. CEA interacted with galectin-3 at the cell surface and cytoplasm of Caco2 and DLD1 CRC cells. Knocking down galectin-3 did not affect CEA expression in CRC cells. However, there was a dose-dependent increase in CRC cell migration upon addition of small amounts of exogenous CEA (≤1ng/ml). Galectin-3 knockdown blocked induction of CRC cell migration by CEA, suggesting interaction between galectin-3 and CEA was necessary for CRC cell migration. Exogenous CEA and galectin-3 synergistically promoted migration of galectin-3 knockdown DLD1 cells. Immunohistochemical analysis showed that CEA co-localized with galectin-3 in CRC patient tissues. In additon, advanced stage CRC patients had higher serum galectin-3 and CEA levels than early stage CRC patients. High serum CEA and galectin-3 levels correlated with advanced N stage and poor survival in CRC patients. These findings suggest interaction between galectin-3 and CEA promotes CRC migration and metastasis, and correlates with poor survival of CRC patients. Thus combinatorial therapy targeting galectin-3 and CEA may improve outcomes for advanced stage CRC patients.
nodes are negative [2]. Relapses often occur in the liver, focal colon, lung ovaries, bone, anastomosis or brain. Metastasis is a multistage process by which cancer cells escape from the primary cancer and establish secondary foci at distant sites. The development and progression of many malignancies including colorectal cancer are associated with aberrant activation of multiple signaling pathways that promote migration, proliferation and survival of tumor cells resulting in metastasis [3]. Our previous study demonstrated that overexpression of galectin-3 increased colon cancer cell migration by activating the K-Ras-Raf-ERK pathway [4].
INTRODUCTION Colorectal cancer (CRC) is one of the most common cancers and a principal cause of death worldwide. The morbidity and mortality rates of CRC continue to increase because CRC is diagnosed at advanced stages in most cases resulting in poor prognosis. The rate of local recurrence and metastasis of CRC is 25% to 50% [1, 2]. The 5-year risk of systemic recurrence in CRC patients after surgical resection is approximately 50% for those with lymph node involvement and 20% to 30% if lymph www.impactjournals.com/oncotarget
61935
Oncotarget
Galectin-3 (also known as Mac-2, CBP-30, hL-31, CBP-35, IgEBP, and LBL) is an endogenous β-galactoside-binding protein belonging to a family of widely distributed carbohydrate binding proteins that are implicated in cell differentiation, adhesion, and malignant transformation. Galectin-3 is involved in the transformation and metastasis of human tumors such as prostate, breast, ovarian, lung, thyroid and pancreas cancers [5–8]. High expression of galectin-3 is correlated with the malignant behavior [9] and metastasis [10, 11] of human colon cancer cells. Galectin-3 regulates metastasis by binding to cell adhesion-related molecules and inhibiting cell–cell and cell–matrix interactions [12], thereby augmenting cancer cell detachment and mobility [13, 14]. Although extracellular expression of galectin-3 modulates the various stages of metastasis in human colon cancer, the mechanistic details of its role in intracellular signaling, migration, and metastatic potential of colon cancer cells are unclear. Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) is expressed on many tumors [15, 16] and is associated with malignancy, particularly enhanced metastasis [17–19]. It functions as a chemoattractant and as an adhesion molecule [20] and promotes metastasis in some tumors [21, 22]. The interaction between galectin-3 and CEA is not clear. Galectin-3 has been shown to bind to human CEA, and lysosome-associated membrane glycoproteins that are involved in cell adhesion [23–25]. Galectin-3 also co-localizes with CEA on the KM12 cell surface [26]. Therefore, we explored the association between galectin-3 and CEA and their potential role in metastasis of colon cancer in this study.
cytoplasm of colorectal cancer cells (Figure 2B). This interaction was blocked by lactose. Interestingly, CEA did not interact with recombinant galectin-3 (rGal3) on the membrane surface and in the cytoplasm (Figure 2A, 2B).
Exogenous CEA and galectin-3 synergistically enhance migration of galectin-3 knockdown DLD-1cells Next, we observed that 1ng/ml CEAincreased the migration of DLD-1 cells that were transfected with scrambled shRNA, but had no effect on DLD-1 cells transfected with shRNA against galectin-3 (Figure 3A, 3B). We observed a dose-dependent effect on DLD1 migration for doses ≤1ng/ml CEA, whereas CEA doses above 1ng/ml decreased migration. Additionally, we observed that addition of recombinant galectin-3 enhanced the migration of shRNA Gal3 DLD-1, thereby demonstrating synergy between galectin-3 and CEA (Figure 3C).
Galectin-3 and CEA expression correlates with advanced stage on CRC IHC staining in 14 patient samples representing different TNM stages (I:2; II:5; III:5; IV:2) showed increased expression of galectin-3 in advanced stages III&IV compared to early stages I&II (H score, III&IV: I&II: 254±31: 136±33, p
Oncotarget, 2017, Vol. 8, (No. 37), pp: 61935-61943 Research Paper
Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis Keng-Liang Wu1,2,3, Eng-Yen Huang4,5, Wen-Ling Yeh1, Chang-Chun Hsiao2,6 and Chung-Mou Kuo1,3 1
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
2
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Kaohsiung, Taiwan
3
Chang Gung University, College of Medicine, Kaohsiung, Taiwan
4
Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
5
School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Kaohsiung, Taiwan
6
Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Correspondence to: Chang-Chun Hsiao, email: [email protected] Keywords: colorectal cancer, galectin-3, carcinoembryonic antigen, cancer cell migration Received: February 09, 2017 Accepted: May 22, 2017 Published: June 27, 2017 Copyright: Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT In this study, we investigated the role of galectin-3 and carcinoembryonic antigen (CEA) in metastasis and survival of colorectal cancer (CRC) patients. CEA interacted with galectin-3 at the cell surface and cytoplasm of Caco2 and DLD1 CRC cells. Knocking down galectin-3 did not affect CEA expression in CRC cells. However, there was a dose-dependent increase in CRC cell migration upon addition of small amounts of exogenous CEA (≤1ng/ml). Galectin-3 knockdown blocked induction of CRC cell migration by CEA, suggesting interaction between galectin-3 and CEA was necessary for CRC cell migration. Exogenous CEA and galectin-3 synergistically promoted migration of galectin-3 knockdown DLD1 cells. Immunohistochemical analysis showed that CEA co-localized with galectin-3 in CRC patient tissues. In additon, advanced stage CRC patients had higher serum galectin-3 and CEA levels than early stage CRC patients. High serum CEA and galectin-3 levels correlated with advanced N stage and poor survival in CRC patients. These findings suggest interaction between galectin-3 and CEA promotes CRC migration and metastasis, and correlates with poor survival of CRC patients. Thus combinatorial therapy targeting galectin-3 and CEA may improve outcomes for advanced stage CRC patients.
nodes are negative [2]. Relapses often occur in the liver, focal colon, lung ovaries, bone, anastomosis or brain. Metastasis is a multistage process by which cancer cells escape from the primary cancer and establish secondary foci at distant sites. The development and progression of many malignancies including colorectal cancer are associated with aberrant activation of multiple signaling pathways that promote migration, proliferation and survival of tumor cells resulting in metastasis [3]. Our previous study demonstrated that overexpression of galectin-3 increased colon cancer cell migration by activating the K-Ras-Raf-ERK pathway [4].
INTRODUCTION Colorectal cancer (CRC) is one of the most common cancers and a principal cause of death worldwide. The morbidity and mortality rates of CRC continue to increase because CRC is diagnosed at advanced stages in most cases resulting in poor prognosis. The rate of local recurrence and metastasis of CRC is 25% to 50% [1, 2]. The 5-year risk of systemic recurrence in CRC patients after surgical resection is approximately 50% for those with lymph node involvement and 20% to 30% if lymph www.impactjournals.com/oncotarget
61935
Oncotarget
Galectin-3 (also known as Mac-2, CBP-30, hL-31, CBP-35, IgEBP, and LBL) is an endogenous β-galactoside-binding protein belonging to a family of widely distributed carbohydrate binding proteins that are implicated in cell differentiation, adhesion, and malignant transformation. Galectin-3 is involved in the transformation and metastasis of human tumors such as prostate, breast, ovarian, lung, thyroid and pancreas cancers [5–8]. High expression of galectin-3 is correlated with the malignant behavior [9] and metastasis [10, 11] of human colon cancer cells. Galectin-3 regulates metastasis by binding to cell adhesion-related molecules and inhibiting cell–cell and cell–matrix interactions [12], thereby augmenting cancer cell detachment and mobility [13, 14]. Although extracellular expression of galectin-3 modulates the various stages of metastasis in human colon cancer, the mechanistic details of its role in intracellular signaling, migration, and metastatic potential of colon cancer cells are unclear. Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) is expressed on many tumors [15, 16] and is associated with malignancy, particularly enhanced metastasis [17–19]. It functions as a chemoattractant and as an adhesion molecule [20] and promotes metastasis in some tumors [21, 22]. The interaction between galectin-3 and CEA is not clear. Galectin-3 has been shown to bind to human CEA, and lysosome-associated membrane glycoproteins that are involved in cell adhesion [23–25]. Galectin-3 also co-localizes with CEA on the KM12 cell surface [26]. Therefore, we explored the association between galectin-3 and CEA and their potential role in metastasis of colon cancer in this study.
cytoplasm of colorectal cancer cells (Figure 2B). This interaction was blocked by lactose. Interestingly, CEA did not interact with recombinant galectin-3 (rGal3) on the membrane surface and in the cytoplasm (Figure 2A, 2B).
Exogenous CEA and galectin-3 synergistically enhance migration of galectin-3 knockdown DLD-1cells Next, we observed that 1ng/ml CEAincreased the migration of DLD-1 cells that were transfected with scrambled shRNA, but had no effect on DLD-1 cells transfected with shRNA against galectin-3 (Figure 3A, 3B). We observed a dose-dependent effect on DLD1 migration for doses ≤1ng/ml CEA, whereas CEA doses above 1ng/ml decreased migration. Additionally, we observed that addition of recombinant galectin-3 enhanced the migration of shRNA Gal3 DLD-1, thereby demonstrating synergy between galectin-3 and CEA (Figure 3C).
Galectin-3 and CEA expression correlates with advanced stage on CRC IHC staining in 14 patient samples representing different TNM stages (I:2; II:5; III:5; IV:2) showed increased expression of galectin-3 in advanced stages III&IV compared to early stages I&II (H score, III&IV: I&II: 254±31: 136±33, p
